Edisnap· @edisnap·
Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF a sequence-context-guided epigenetic repair strategy — combining computational identification of R882H-preferential CpG targets (using the known +3-position flanking sequence preference profile) with catalytically inactive Cas9 fused to TET1 catalytic domain (dCas9-TET1) delivered via lipid nanoparticle to hematopoietic stem and progenitor cells (HSPCs) in aged mice (18–24 months, mixed sex, C57BL/6J background carrying hDNMT3A R882H in the hematopoietic compartment) — is administered as a multiplexed sgRNA panel targeting the top 20–50 aberrantly hypermethylated CpG loci predicted by R882H sequence-context modeling,
THEN measurable reversal of the accumulated R882H-driven hypermethylation signature (≥40% reduction in methylation beta values at targeted CpGs by bisulfite sequencing), partial restoration of the epigenetic age clock toward younger reference animals, and attenuation of motor and neurological pathology (CatWalk gait score normalization) will be observed within 16 weeks of treatment,
BECAUSE the following causal chain is supported by the evidence:

IF a bicistronic nuclear expression cassette co-encoding (i) codon-optimized allotopic MT-CYB fused to the SOD2 mitochondrial targeting sequence (MTS) and the SOD2 3' UTR mRNA-localization element, together with (ii) a co-expressed, matrix-targeted UQCC2 "assembly escort" fragment (residues 1–130, containing the CYB-binding domain but truncated to remove the ribosome-docking domain that is irrelevant outside the mitoribosome context) — delivered via AAV2/9 intravitreally (for optic models) or transfection into MT-CYB-mutant human fibroblasts —
is administered to patient-derived MT-CYB-mutant fibroblasts (Phase 1) and aged (18–22 month) C57BL/6J male mice with confirmed Complex III decline (Phase 2),
THEN a restoration of Complex III enzymatic activity to ≥50% of age-matched wild-type levels (measured by the decylubiquinol spectrophotometric assay of Krähenbühl et al., validated for fibroblasts and isolated mitochondria) (assay validated in fibroblasts and tissues)[https://pubmed.ncbi.nlm.nih.gov/7834868/], accompanied by ≥75% mitochondrial colocalization of allotopic CYB with TOM20 by immunofluorescence, and incorporation of CYB into the ~480 kDa CIII₂ homodimer and I+III₂+IV supercomplexes detectable by Blue-Native PAGE, will be observed —
BECAUSE the following causal chain operates:

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF a sequential epigenetic priming protocol — CI-994 (10 mg/kg i.p., 3×/week for 2 weeks) administered as a pre-treatment window prior to intrastriatal AAV9-shPTBP1 injection (5×10¹¹ vg, single dose) — is delivered to aged (18–20 month) male C57BL/6J mice bearing unilateral 6-OHDA MFB lesions, with conversion validated using stringent Aldh1l1-CreER dual-recombinase lineage tracing (not GFAP-promoter AAV alone),
THEN the number of stereologically confirmed, lineage-traced TH+/NeuN+/tdTomato+ neurons in the ipsilateral striatum at 12 weeks post-AAV will be ≥40% greater than in the AAV9-shPTBP1 + vehicle group (with no CI-994 pre-treatment), with corresponding partial rescue of striatal dopamine and DOPAC by HPLC-ECD and improved cylinder test asymmetry, and ChIP-seq of FACS-sorted GFAP+ striatal astrocytes at the end of the 2-week priming window will show significant enrichment of H3K27ac at neurogenic loci including Ascl1, Neurod1, Nurr1, and Pitx3 compared to vehicle-treated astrocytes,
BECAUSE the following causal chain operates sequentially:

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF a GK-NaV multi-valent nanovaccine co-delivering GPNMB extracellular domain peptide and uPAR (PLAUR) extracellular domain peptide at a 1:2 molar ratio (uPAR-biased to prevent GPNMB immunodominance), formulated with R848 (TLR7/8 agonist) and GM-CSF and administered subcutaneously to 18-month-old male and female C57BL/6J mice (3-dose primary series, weeks 0/3/6, plus a single boost at month 3), is co-administered concurrently with a low-dose, intermittent oral senolytic sensitizer targeting Senescent Cell Anti-Apoptotic Pathways (SCAPs — specifically BCL-2/BCL-XL as identified by transcriptomic network analysis),
THEN compared to either the dual-antigen vaccine alone, SCAP inhibition alone, or single-antigen vaccines (GPNMB-only or uPAR-only), the combination arm will demonstrate: (a) ≥50% reduction in GPNMB+ senescent cell burden in visceral adipose and aortic endothelium by IHC at 12 weeks post-vaccination; (b) ≥50% reduction in uPAR+ senescent cell burden in liver (pericentral zone), lung interstitium, and skeletal muscle by IHC; (c) ≥40% reduction in composite SASP plasma panel (IL-6, MMP-3, GDF-15, PAI-1); and (d) statistically significant improvements in grip strength, treadmill endurance, and metabolic parameters (glucose tolerance, body composition) versus all monotherapy controls, measured at 12 and 24 weeks post-treatment initiation,
BECAUSE of the following causal chain:

Background: Adult-onset Still disease (AOSD) carries a 12–17% risk of macrophage activation syndrome (MAS), a life-threatening complication. Current monitoring relies on ferritin thresholds, which reflect established hemophagocytic activity rather than early immune dysregulation. IL-18 is pathognomically elevated in AOSD, but total IL-18 levels plateau early and lack predictive granularity. IL-18 binding protein (IL-18BP) serves as a natural decoy receptor, and the ratio of free IL-18 to total IL-18BP may reflect the exhaustion of endogenous buffering capacity before clinical MAS develops.
Hypothesis: Serial measurement of the free IL-18/IL-18BP molar ratio in AOSD patients will demonstrate a critical threshold crossing (ratio >0.2) that predicts MAS onset 3–8 weeks before serum ferritin exceeds 10,000 ng/mL. This threshold reflects saturation of endogenous IL-18BP buffering capacity, after which unopposed free IL-18 drives IFN-γ–dependent macrophage hyperactivation via a feed-forward loop.
Testable predictions:

This research explores the hypothesis that specific bioactive signaling peptides can significantly influence the biological processes associated with aging. The core premise is that targeting systemic inflammation and cellular maintenance through peptide intervention can extend healthspan.
Certain bioactive signaling peptides promote longevity by reducing chronic low-grade inflammation, improving mitochondrial function, and enhancing cellular repair pathways such as autophagy.
Aging is characterized by a gradual decline in cellular function. Bioactive peptides, known for high specificity and low toxicity, represent a promising class of therapeutic agents that can mimic or modulate existing biological signals to counteract these age-related changes and extend human healthspan.

IF a sequential two-phase intervention — oral gavage of dasatinib (5 mg/kg) + quercetin (50 mg/kg) for 3 consecutive days followed 7 days later by mifepristone (10 mg/kg IP, 3×/week, 8 weeks) — is administered to 18-month-old male and female C57BL/6J mice (and age-matched PINK1-knockout controls),
THEN compared with D+Q-only controls, mifepristone-treated wildtype mice will show ≥40% reduction in p16INK4a+ cell frequency and SA-β-gal activity in liver, kidney, and gastrocnemius muscle, a ≥1.5-fold increase in mt-Keima acid:neutral ratio in freshly isolated hepatocytes and muscle fibers, and ≥30% reduction in plasma IL-6 and MCP-1 — with complete or near-complete abolition of all three effects in PINK1-KO cohorts —
BECAUSE the following causal chain, grounded in the Evidence Set, is operative:
Senescent hepatocytes and myocytes harbor structurally dysfunctional mitochondria with reduced fatty acid oxidation capacity and compromised membrane potential, constituting the accumulated mitochondrial damage that drives the senescent phenotype in aged tissue rather than merely correlating with it. (Senescent hepatocytes display mitochondrial dysfunction)[https://doi.org/10.1038/ncomms15691]
Damaged mitochondria in senescent and paracrine-stressed bystander cells generate cytosolic mtDNA and reactive oxygen species that fuel retrograde mitochondria-to-nucleus signaling; targeted depletion of mitochondria in senescent cells suppresses a 31-gene SASP mRNA panel and reduces IL-8 protein, demonstrating that mitochondrial status is a mechanistic upstream driver of the SASP, not

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF a tripartite nuclear-recoded MT-CYB construct — comprising (a) the SOD2 mitochondrial targeting sequence (MTS) N-terminal fusion, (b) the SOD2 3′UTR for mRNA surface localization, and (c) targeted hydrophobicity-reduction mutagenesis of the two most GRAVY-scored transmembrane helices (predicted TM-IV and TM-V) limited to conservative Ile→Val and Leu→Ala substitutions at non-heme-coordinating, non-ubiquinone-contacting residue positions — is delivered first as pseudouridine/5-methylcytosine (Ψ/5mC) modified mRNA and subsequently via AAV9 to MT-CYB-null cybrid cells generated by DdCBE-mediated introduction of a premature stop codon in the endogenous MT-CYB locus,
THEN the allotopically expressed CYB protein will (i) localize to the mitochondrial inner membrane as confirmed by immunogold electron microscopy, (ii) assemble into the dimeric bc1 complex detectable by Blue Native PAGE, (iii) restore Complex III enzymatic activity (cytochrome c reductase assay) to ≥25% of isogenic wild-type levels, and (iv) confer rescue of OXPHOS-dependent proliferation on glucose-free galactose medium within 14 days post-transfection,
BECAUSE the causal chain proceeds as follows:

IF a single intravenous dose of AAV9 encoding a human-codon-optimized OsDJ-1C transgene under a constitutive CAG promoter (1×10¹¹ vg/mouse) is administered to 18-month-old male and female C57BL/6J mice carrying established dicarbonyl damage (elevated tissue MG-H1, CEdG DNA adducts, and a depleted GSH/GSSG ratio consistent with aged tissue),
THEN quantitative LC-MS/MS measurement at 6 months post-injection will reveal ≥40% reduction in hepatic and renal tissue-free MGO concentrations, ≥30% reduction in MG-H1 adduct density on short-to-medium turnover proteins (assessed by targeted proteomics), a measurable decrease in CEdG DNA adduct burden in liver (assessed by immunoslot-blot and LC-MS), and partial restoration of endogenous PARK7/DJ-1 deglycase activity on long-lived glycated protein substrates, compared with age-matched AAV9-GFP controls,
BECAUSE the following causal chain operates in aged mammalian tissue:

IF systemic SkQ1 (5 nmol/kg/day via drinking water, 12 weeks) is administered to 22–24-month-old C57BL/6J mice of both sexes carrying the mito-QC mitophagy reporter transgene,
THEN a measurable reduction (≥20% decrease) in the fractional burden of large-scale mtDNA deletions across cardiac and skeletal muscle tissue will be observed at endpoint (week 12), accompanied by a ≥30% increase in basal mitophagic flux (mito-QC lysosomal:mitochondrial red-to-green puncta ratio) in the same tissues and normalization of lysosomal cathepsin B/D activity to levels observed in 6-month-old controls,
BECAUSE the following causal chain operates sequentially:
In aged mice (24 months), chronic mitochondrial ROS production generates lipid peroxidation products and protein carbonyls that accumulate as lipofuscin within lysosomes, physically and chemically inactivating cathepsins B, D, and L — the proteases required to degrade mitochondrial cargo delivered by completed mitophagosomes. This lysosomal blockade creates a downstream bottleneck that traps ubiquitinated, PINK1/Parkin-tagged damaged mitochondria in autolysosomes without degrading them, causing stalled mitophagic flux despite intact upstream recognition machinery. (Evidence: SkQ1 prevents lipofuscin formation and age-dependent autophagy decline by mitigating lipid peroxidation — Skulachev et al., Aging, 2017, cited in Evidence Set.)
Aged cardiac and hippocampal tissue show a precipitous decline in mitophagic flux relative to young controls, quantified using mito-QC and mt-Keima reporter systems; this decline is not attributa

IF aged human hematopoietic stem cells (HSCs; donors >65 years, purified Lin⁻CD34⁺CD38⁻CD90⁺ fraction) are subjected to a sequential ex vivo lysosomal reset protocol — first a 16-hour exposure to trehalose (100 mM) to activate TFEB-mediated lysosomal biogenesis and clear accumulated intracellular substrate, followed immediately by a 16-hour exposure to bafilomycin A1 (BafA1; 3 nM) to suppress v-ATPase hyperactivation rebound — prior to xenotransplantation into sub-lethally irradiated NSG mice,
THEN recipients will demonstrate ≥6-fold improvement in long-term human CD45⁺ chimerism at 16 weeks post-transplant relative to untreated aged HSC controls, with balanced myeloid/lymphoid output (CD33⁺:CD19⁺ ratio <2, matching young donor reference), and successful secondary engraftment in ≥60% of serially transplanted hosts,
BECAUSE the following mechanistic chain operates:
Aged HSCs accumulate undegraded intracellular substrates (protein aggregates, damaged organelles, lipofuscin-like material) due to insufficient lysosomal biogenesis relative to the rate of damage accrual — this substrate overload drives compensatory v-ATPase upregulation to acidify and process the backlog, producing the hyperactivated lysosomal phenotype observed in aged HSCs. SPECULATIVE link — supported indirectly by the neural stem cell evidence showing that reduced autophagic flux into acidified lysosomes characterizes aged quiescent stem cells, with accumulated GFP-LC3-positive material indicating unresolved substrate burden
Trehalose, acting as

IF a codon-optimized fusion protein comprising Pyrococcus furiosus RNase HII (PfuRNaseHII) C-terminally linked via a flexible (Gly₄Ser)₃ linker to a tandem dual-copy TRF2 TRFH-docking peptide (YRLSP×2) and an SV40 nuclear localization signal (NLS), packaged within an AAV2/9 hybrid capsid, is delivered by intratumoral injection at 1×10¹¹ vector genomes per mouse into established subcutaneous U2OS or Saos-2 xenografts (100–150 mm³) in male NSG mice aged 6–8 weeks,
THEN over 28 days the following will be observed: (1) ≥50% reduction in C-circle abundance by rolling-circle amplification qPCR (baseline sensitivity 0.1 attomoles circular template), (2) ≥40% reduction in ALT-associated PML body (APB) frequency per nucleus (scoring ≥200 nuclei per condition by PML/TRF2 co-immunofluorescence), and (3) ≥3-fold increase in telomere dysfunction-induced foci (TIF) measured by γH2AX/telomeric FISH co-localization, relative to AAV2/9-GFP control-injected xenografts,
BECAUSE the following causal chain operates:
ATRX loss elevates TERRA transcription and R-loop accumulation at telomeres. In ATRX-null U2OS and Saos-2 cells, failure to deposit histone H3.3 at telomeres abolishes heterochromatic repression, leading to pervasive TERRA upregulation and the chronic formation of telomeric RNA:DNA hybrids that are the mechanistic substrate of the ALT pathway (Arora et al., 2014, Science, as reviewed in Evidence Set).
TERRA R-loops directly nucleate the BIR-based recombination events that produce C-circles and sustain APBs. R-loop formation at telomeres loads RAD52 and drives b

IF a sequential two-phase intervention consisting of (Phase A) systemically administered TFSA (trifluoromethylsulfonyl-functionalized) pH-buffering polymeric nanoparticles (10–25 mg/kg i.p., 2×/week, 4 weeks) to chemically re-acidify RPE lysosomes, followed by (Phase B) subretinal injection of a self-complementary AAV9 (scAAV9) vector encoding human ATP6V1H (V-ATPase V1 H-subunit) under the VMD2/BEST1 RPE-specific promoter with a C-terminal HA epitope tag, is administered to aged (18–22 month) male and female C57BL/6 mice with established RPE lysosomal dysfunction,
THEN LysoSensor Yellow/Blue DND-160 ratiometric imaging of RPE flat mounts will show measurable re-acidification of RPE lysosomes (pH shift from ~5.5–5.8 baseline in aged RPE toward the youthful ~4.7–5.0 range), accompanied by a ≥30% reduction in RPE lipofuscin/A2E autofluorescence, structural preservation of the photoreceptor-RPE interface on OCT, and maintained ERG b-wave amplitude relative to vehicle-treated aged controls,
BECAUSE:

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach for refractory systemic lupus erythematosus (SLE), achieving drug-free remission in early case series (Mackensen et al., Nat Med 2022; Müller et al., NEJM 2024). However, response heterogeneity remains unexplained — some patients achieve sustained seroconversion of anti-dsDNA with durable clinical remission, while others experience incomplete B-cell depletion or early reconstitution with persistent autoantibody production. No validated biomarker currently predicts the depth or duration of CAR-T–mediated B-cell aplasia in autoimmune indications.
We hypothesize that pre-treatment circulating T follicular helper (cTfh) cell frequency — specifically the ICOS+PD-1++ subset — combined with serum CXCL13 trajectory slope over the 4 weeks preceding CAR-T infusion predicts:
Patients with high cTfh ICOS+PD-1++ frequency (>15% of CD4+ T cells) and rising CXCL13 slope (>2 pg/mL/week) harbor active germinal center reactions that generate treatment-resistant long-lived plasma cells in survival niches (bone marrow, inflamed tissue). These patients will exhibit shorter B-cell aplasia duration (<12 weeks) and lower probability of sustained serological remission despite adequate CAR-T expansion, because the underlying Tfh-driven germinal center activity rap

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF a combinatorial, asymmetrically targeted pharmacological regimen — consisting of (i) intravenous delivery of young (3-month) donor mesenchymal stem cells (MSCs) pre-conditioned with SC-79 (an Akt activator, 5 µM, 24h ex vivo), which upregulates Miro1 protein expression and loads healthy mitochondria onto the kinesin motor complex, combined with (ii) systemic low-dose rapamycin (2 mg/kg every other day) administered to aged recipient mice to suppress aberrant mTOR hyperactivation in aged tissue-resident cells — is administered to 22-month-old male C57BL/6 mice for 8 weeks,
THEN a net increase in directionally biased (donor-to-recipient) TNT-mediated mitochondrial transfer to aged skeletal muscle satellite cells and hepatocytes will be observed — quantified as ≥40% increase in donor-mitochondria-positive aged cells (via mito-Dendra2 photoconversion tracing), accompanied by ≥30% reduction in mtDNA heteroplasmy burden in aged tissue, restored Complex I-driven oxygen consumption rate (OCR) ≥25% above vehicle-aged controls, and ≥50% reduction in SASP cytokine panel (IL-6, IL-8, MMP3) in treated tissue — measured at 4 and 8 weeks post-initiation,
BECAUSE the following step-by-step causal chain operates:

IF a sequential-then-concurrent pharmacological regimen of MitoQ (mitoquinone mesylate, 500 µM in drinking water, administered ad libitum) followed by bezafibrate (0.5% w/w in chow) — with MitoQ initiated two weeks prior to bezafibrate co-administration to pre-condition the mitochondrial redox environment — is administered to aged C57BL/6J male mice (22–24 months), compared to vehicle control, MitoQ monotherapy, and bezafibrate monotherapy arms,
THEN a measurable reduction in hippocampal mutant mtDNA heteroplasmy fraction (≥20% reduction in the ratio of deletion-bearing to wild-type mtDNA copies, quantified by long-range PCR and droplet digital PCR), combined with a ≥30% increase in hippocampal mtDNA copy number, ≥25% reduction in 4-hydroxynonenal (4-HNE) adducts, and statistically significant improvement in Morris Water Maze escape latency and probe trial performance relative to vehicle-treated aged controls, will be observed,
BECAUSE the following step-by-step causal chain operates:
In the aged brain, elevated mitochondrial ROS drives ongoing somatic mtDNA point mutations and deletions via oxidative base damage (8-oxoguanine) and strand-break-mediated rearrangements, progressively enriching the pool of deletion-bearing mtDNA molecules and worsening electron transport chain (ETC) dysfunction. (Mitochondrial DNA replication machinery contributes to mutagenesis and age-related disease accumulation)[https://doi.org/10.1016/j.arr.2016.04.006]
MitoQ, accumulating ~500-fold within the mitochondrial matrix via its TPP+ cation anchor, quenches superoxide and lipid peroxy

IF dual AAV-mediated chromatin restoration — intratumoral AAV9-DAXX (week 0) followed by AAV9-ATRX (week 1), both at ~1×10¹¹ vg/tumor, administered without any concurrent G-quadruplex (G4) stabilizer — is delivered to Saos-2 ALT-positive osteosarcoma xenografts in female athymic nude mice (6–8 weeks), and then supplemented at week 3 with intratumoral AAV9-RNaseH1 overexpression to resolve residual TERRA R-loops at telomeres,
THEN ≥70% reduction in APB foci (immuno-FISH, PML/telomere colocalization) and ≥70% reduction in C-circle signal (quantitative rolling-circle amplification C-circle assay) will be observed by week 6 compared to vehicle-AAV controls, with secondary reductions in telomere sister-chromatid exchange (T-SCE) frequency and telomere length heterogeneity,
BECAUSE of the following mechanistic chain:
Loss of ATRX is causally sufficient to activate ALT, as demonstrated by C-circle production, APB formation, fragile telomeres, and elevated T-SCEs in ATRX-null sarcoma models (ATRX loss drives ALT hallmarks in primary CAST/EiJ sarcoma)[https://doi.org/10.1101/2023.11.06.565874]. Restoring ATRX expression re-establishes G4 resolution at TERRA-rich telomeric repeats and re-deposits H3.3 into heterochromatin, directly suppressing ALT (ATRX restoration suppresses C-circles and APBs)[https://doi.org/10.1038/ncomms8538].
DAXX, ATRX's obligate chromatin-remodeling partner, independently and rapidly suppresses ALT in the osteosarcoma line G292 when stably re-expressed; this requires intact C-terminal SUMO-interaction motif–mediated PML body localization and act

IF a logic-gated, bispecific AND-gate CAR-T cell construct co-targeting Fibroblast Activation Protein (FAP) and Urokinase Plasminogen Activator Receptor (uPAR) — each encoded as tandem scFv domains linked to split-signaling architecture (anti-FAP scFv driving CD3ζ; anti-uPAR scFv driving 4-1BB co-stimulation, requiring simultaneous engagement of both receptors for full T-cell activation) at a dose of 5×10⁶ cells/mouse administered intravenously is administered to 10–12-week-old male C57BL/6J mice at peak CCl4-induced liver fibrosis (week 8 of CCl4 protocol),
THEN liver collagen content will decrease by ≥40% (measured by Sirius Red morphometry and hydroxyproline assay), histological fibrosis score (METAVIR/Ishak) will improve by ≥2 stages, and serum ALT/AST will normalize to within 1.5× upper reference limits within 21 days post-infusion, with significantly attenuated on-target off-tumor toxicity (cardiac fibroblast depletion, bone marrow stromal damage, and cytokine release syndrome severity) compared to single-target anti-FAP scFv-CD3ζ-4-1BB CAR-T cells,
BECAUSE the following causal chain operates:

Background: IgA vasculitis (Henoch-Schönlein purpura) causes renal involvement in 20–50% of cases, yet no reliable early biomarker distinguishes self-limited cutaneous disease from nephritis-destined trajectories. The lectin complement pathway, activated by galactose-deficient IgA1 (Gd-IgA1) immune complexes binding mannose-binding lectin (MBL), may represent the mechanistic bridge.
Hypothesis: In patients with IgA vasculitis, the combination of (1) MBL2 genotype–serum MBL discordance (high-expressing genotype with paradoxically declining serum MBL, indicating consumption by Gd-IgA1 complexes) and (2) rising Gd-IgA1/total IgA1 ratio slope >0.15 per week predicts histologically confirmed renal involvement 6–14 weeks before the first abnormal urinalysis, with AUROC >0.85.
Proposed mechanism: Gd-IgA1 forms immune complexes that bind MBL via exposed GalNAc residues, activating MASP-2 and generating C4d deposition in mesangial tissue. In patients with high-expressing MBL2 haplotypes (HYPA/LYQA), serum MBL consumption reflects ongoing lectin pathway activation in renal mesangium before sufficient glomerular damage produces detectable proteinuria or hematuria.
Testable predictions:

IF hydroxypropyl-beta-cyclodextrin (HPβCD) is administered via intravitreal injection (1.5 μL, ~500 mM, weekly × 4 doses based on MβCD dosing precedent) to aged Abca4−/− male and female mice (9 months, at peak bisretinoid burden) in a sequential, two-phase protocol — HPβCD clearance first (weeks 1–4), followed by subretinal dual-vector AAV8-ABCA4 gene therapy (1.0–1.5 × 10¹² gc/mL per eye, week 5) —
THEN RPE A2E and total bisretinoid content will be reduced by ≥50% relative to AAV8-ABCA4 monotherapy, ONL thickness will be preserved at ≥80% of young wild-type reference at 6-month post-treatment assessment, and scotopic ERG b-wave amplitudes will be improved ≥30% relative to age-matched vehicle controls,
BECAUSE the causal chain proceeds through the following steps:
HPβCD extracts excess free cholesterol from RPE lysosomal membranes, disrupting mTORC1 anchoring at the lysosomal surface and thereby allowing TFEB dephosphorylation and nuclear translocation — a mechanism demonstrated in lysosomal storage disease cells where HPβCD activates TFEB, induces the CLEAR network, and drives autophagic flux (HPβCD promotes TFEB-mediated autophagy activation)[https://doi.org/10.1074/jbc.m113.506246].
TFEB nuclear translocation in RPE cells upregulates lysosomal biogenesis and exocytosis genes, causing lysosomes loaded with indigestible A2E and bisretinoids to fuse with the basolateral RPE membrane and expel their contents into the sub-RPE space for choriocapillaris clearance — analogous to how MβCD drove bisretinoid reduction ex vivo and in vivo in Abca4−/− *

The mucosal origins hypothesis of rheumatoid arthritis (RA) posits that citrullination-driven immune tolerance breakdown initiates at extra-articular sites years before joint inflammation. Porphyromonas gingivalis remains the only prokaryote expressing a peptidylarginine deiminase (PPAD) capable of generating citrullinated autoantigens (fibrinogen, α-enolase, vimentin) implicated in anti-citrullinated protein antibody (ACPA) production.
We hypothesize that serial quantification of salivary P. gingivalis PPAD gene copy number via qPCR, combined with subgingival pocket depth mapping and serum pre-ACPA IgA levels, constitutes a composite mucosal-origin biomarker panel that predicts ACPA seroconversion and clinical RA onset 2–5 years before articular manifestations with >75% sensitivity and >80% specificity.

This research addresses a critical limitation in current oncological treatments: the lack of selectivity in chemotherapy, which often leads to severe systemic toxicity. By utilizing functionalized nanoparticles, this study proposes a method to focus therapeutic delivery directly to tumor sites.
Targeted functionalized nanoparticles improve chemotherapy selectivity and reduce systemic toxicity. The hypothesis posits that by attaching tumor-specific ligands to nanoparticles, we can significantly increase drug accumulation within tumor cells while sparing healthy systemic tissue.
Based on the analysis of Hypothesis H5, several key outcomes are expected:
The experimental validation involves:
